drugset / Trial / NCT04291456
Minocycline in MS: Confirmation of Benefit
Phase 3
Terminated
9 enrolled
University of Calgary
Hotchkiss Brain Institute, University of Calgary · collabMultiple Sclerosis Society of Canada · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, single-arm clinical trial. Trial participants will include men and women, aged 18-60 years who have had a first demyelinating event within the previous 180 days and who have brain magnetic resonance imaging (MRI) with at least two brain T2 lesions which are at least 3 mm in diameter, and at least one of which is ovoid or periventricular or infra-tentorial. Treatment with minocycline until the endpoint is reached or to a maximum of 24 months or until the last-enrolled participant reaches their 12 month visit.
Timeline
- Start
- 2020-01-31
- Primary completion
- 2022-12-16
- Completion
- 2022-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Minocycline | Small molecule | 100 mg | Oral |